13F Holdings
中文EN

BCTX BriaCell Therapeutics Corp.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1610820 · Fiscal year ends 07/31

Financial factors as of 2026-07-31 (2026Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-32.7%
TTM EPS YoY88.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-203.6%
ROA-154.3%
ROIC (approx.)-408.8%
Asset turnover—

Leverage & solvency

Liabilities / assets34.0%
Debt / equity0.00x
Current ratio2.76x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-07-31FY20252025-07-31FY20242024-07-31FY20232023-07-31FY20222022-07-31
Income statement
Revenue—————
R&D expense$29.24M$21.27M$27.18M$15.34M$8.02M
SG&A expense$6.82M$5.93M$6.15M$7.94M$7.27M
Operating income-$36.05M-$27.20M-$33.33M-$23.27M-$15.29M
Interest expense$29,631$36,979——$979
Pretax income$35.33M$26.56M$4.93M$20.30M-$26.84M
Net income-$34.90M-$26.31M-$4.79M-$20.30M-$26.84M
EBITDA-$35.95M-$27.11M-$33.26M—-$15.27M
EPS (basic)-6.97-62.19-43.68-1.30-1.73
EPS (diluted)-6.97-62.19-43.68-1.30-1.73
Weighted avg. shares (diluted)5.01M423,114109,69915.62M15.49M
Balance sheet
Cash & equivalents$9.85M$10.49M$862,089$21.25M$41.04M
Short-term investments$10.69M$7.37M———
Receivables———$18,873$24,103
Current assets$22.04M$19.93M$3.65M$26.95M$42.35M
PP&E, net$319,804$296,819$388,175$2,500$2,500
Intangibles$169,254$184,525$199,796$215,068$230,339
Total assets$23.58M$21.65M$5.87M$27.16M$42.58M
Current liabilities$7.98M$3.98M$7.46M$1.80M$941,087
Total liabilities$8.02M$4.32M$8.56M$30.94M$32.25M
Shareholders' equity$16.40M$17.88M-$2.38M-$3.78M$10.33M
Shares outstanding8.71M1.88M121,90715.98M15.52M
Cash flow statement
Operating cash flow-$28.65M-$28.17M-$24.13M-$23.74M-$12.48M
Capital expenditure$127,049—$456,801——
Free cash flow-$28.78M—-$24.58M——
Investing cash flow-$3.81M-$7.65M-$681,801——
Financing cash flow$31.81M$45.45M$4.42M$3.95M-$3.74M
Depreciation & amortization$104,064$91,356$68,626—$15,272
Stock-based compensation$1.13M$656,829$1.80M$2.19M$3.07M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.